Orthopedic medtech company Meduloc has closed $4 million in series B financing.
The funding will support Meduloc’s controlled alpha launch, generation of clinical evidence and development of commercial infrastructure, according to an Aug. 6 news release from the company.
Meduloc has developed a flexible nitinol intramedullary platform that is FDA-cleared. The single-use system is designed for long-bone fracture applications in adult and pediatric patients.
The controlled alpha launch, expected to start in August 2026, will build clinical experience across multiple fracture applications and collect surgeon feedback to support future commercial expansion.
The financing round was led by GenHenn Capital, with participation from existing and new investors, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
